CAR T-cell treatment numbers may double by 2030 if committee is successful

Chimeric antigen receptor (CAR) T-cell therapy advocacy group CAR T Vision aims to double the number of eligible patients receiving CAR T-cell therapy by 2030.

Approximately 50,000 patients have been treated since it was approved by the FDA in 2017.

George Eastwood, Executive Director of the Emily Whitehead Foundation, is a recent member of the CAR T Vision Steering committee.

The committee recommends increasing CAR T-cell therapy awareness, expanding the resources needed to deliver the therapy and developing sustainable financing models.

“Getting together as a group and doubling the number of patients is a great, ambitious goal, but there are so many levers, from the policy side to the payer side to the patient side,” Eastwood said during a recent Managed Healthcare Executive interview. “We need to agree to those KPIs and measurements together as a team, while keeping the patient in mind.”